CATX - Perspective Therapeutics, Inc. News

BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price T

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) wit

B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Ne

Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight

Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimat

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the a

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared t

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP

Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERI

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Res

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Com

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics

Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CA

Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gast

The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Co

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed comp

Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contrib

proactiveinvestors.com

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor

proactiveinvestors.com

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor

Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharm

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirm

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting,

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Comp

Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/

The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Stu

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compan

seekingalpha.com

Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estima

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the a

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compan

Earnings Scheduled For May 11, 2026

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

seekingalpha.com

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics (CATX) is advancing radiopharmaceutical therapies, with a pivotal data read

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer T

Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharm

HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with

B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an

UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8

UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the pr

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio

RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $14

RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperf

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estim

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the

Earnings Scheduled For March 16, 2026

This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Piper Sandler Initiates Coverage On Perspective Therapeutics with Overweight Rating, Announces Price

Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with

12 Health Care Stocks Moving In Monday's Intraday Session

HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $12

HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with